Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

Fumitaka Takeshita, Lubna Patrawala, Mitsuhiko Osaki, Ryou U. Takahashi, Yusuke Yamamoto, Nobuyoshi Kosaka, Masaki Kawamata, Kevin Kelnar, Andreas G. Bader, David Brown, Takahiro Ochiya

Research output: Contribution to journalArticle

332 Citations (Scopus)

Abstract

Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalMolecular Therapy
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

cdc Genes
MicroRNAs
Prostate
Down-Regulation
Growth
Neoplasms
Prostatic Neoplasms
Cell Proliferation
Neoplasm Metastasis
Bone and Bones
Tail
Veins
Injections
Cell Cycle Checkpoints
Heterografts
Transfection
Carcinogenesis
Animal Models
Gene Expression
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R. U., Yamamoto, Y., Kosaka, N., ... Ochiya, T. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Molecular Therapy, 18(1), 181-187. https://doi.org/10.1038/mt.2009.207

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. / Takeshita, Fumitaka; Patrawala, Lubna; Osaki, Mitsuhiko; Takahashi, Ryou U.; Yamamoto, Yusuke; Kosaka, Nobuyoshi; Kawamata, Masaki; Kelnar, Kevin; Bader, Andreas G.; Brown, David; Ochiya, Takahiro.

In: Molecular Therapy, Vol. 18, No. 1, 01.01.2010, p. 181-187.

Research output: Contribution to journalArticle

Takeshita, F, Patrawala, L, Osaki, M, Takahashi, RU, Yamamoto, Y, Kosaka, N, Kawamata, M, Kelnar, K, Bader, AG, Brown, D & Ochiya, T 2010, 'Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes', Molecular Therapy, vol. 18, no. 1, pp. 181-187. https://doi.org/10.1038/mt.2009.207
Takeshita, Fumitaka ; Patrawala, Lubna ; Osaki, Mitsuhiko ; Takahashi, Ryou U. ; Yamamoto, Yusuke ; Kosaka, Nobuyoshi ; Kawamata, Masaki ; Kelnar, Kevin ; Bader, Andreas G. ; Brown, David ; Ochiya, Takahiro. / Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. In: Molecular Therapy. 2010 ; Vol. 18, No. 1. pp. 181-187.
@article{a5de526aac6149f183b3168782c5310f,
title = "Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes",
abstract = "Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.",
author = "Fumitaka Takeshita and Lubna Patrawala and Mitsuhiko Osaki and Takahashi, {Ryou U.} and Yusuke Yamamoto and Nobuyoshi Kosaka and Masaki Kawamata and Kevin Kelnar and Bader, {Andreas G.} and David Brown and Takahiro Ochiya",
year = "2010",
month = "1",
day = "1",
doi = "10.1038/mt.2009.207",
language = "English",
volume = "18",
pages = "181--187",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

AU - Takeshita, Fumitaka

AU - Patrawala, Lubna

AU - Osaki, Mitsuhiko

AU - Takahashi, Ryou U.

AU - Yamamoto, Yusuke

AU - Kosaka, Nobuyoshi

AU - Kawamata, Masaki

AU - Kelnar, Kevin

AU - Bader, Andreas G.

AU - Brown, David

AU - Ochiya, Takahiro

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.

AB - Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=74149083873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149083873&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.207

DO - 10.1038/mt.2009.207

M3 - Article

C2 - 19738602

AN - SCOPUS:74149083873

VL - 18

SP - 181

EP - 187

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -